The global burden of Alzheimer’s disease, a relentless neurodegenerative disorder affecting tens of millions worldwide, has spurred an urgent quest for effective therapies. Recent advancements have brought forth treatments like lecanemab, a monoclonal antibody marketed under the brand name Leqembi, which has demonstrated an ability to slow cognitive decline by targeting the harmful amyloid plaques characteristic of the disease. While its clinical benefits have garnered significant attention, the precise cellular and molecular mechanisms underpinning its efficacy remained a subject of intense scientific inquiry. Now, groundbreaking research spearheaded by scientists at VIB and KU Leuven has definitively unraveled how this pivotal therapy operates, identifying a critical component of the antibody that orchestrates the brain’s immune response to clear these toxic protein aggregates. This discovery provides the first comprehensive explanation of lecanemab’s action, offering invaluable insights for the design of future, potentially safer and more potent Alzheimer’s interventions.
Alzheimer’s disease is the most common cause of dementia, characterized pathologically by the accumulation of misfolded proteins in the brain. The hallmark features include extracellular deposits of amyloid-beta peptides, forming senile plaques, and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. These insidious protein clusters are believed to initiate a cascade of neurotoxic events, impairing synaptic function, damaging neurons, and ultimately leading to the progressive cognitive decline and memory loss that define the disease. The "amyloid cascade hypothesis," while complex and debated, has long served as a guiding principle for therapeutic development, positing that targeting amyloid-beta aggregation could prevent or slow the neurodegenerative process.
Within the brain’s intricate ecosystem, a specialized population of immune cells known as microglia plays a crucial role in maintaining neural homeostasis. These resident macrophages act as the central nervous system’s primary defense mechanism, continuously surveying the brain environment, clearing cellular debris, and responding to injury or infection. In the context of Alzheimer’s disease, microglia are observed to congregate around amyloid plaques, seemingly attempting to engulf and remove these pathological structures. However, in the diseased state, these cells often become dysfunctional, adopting a pro-inflammatory or senescent phenotype that renders them ineffective at plaque clearance, or even contributes to neuroinflammation and neuronal damage. The challenge for researchers has been to devise strategies that restore or enhance the microglia’s natural, protective functions.
Lecanemab represents a significant step forward in this therapeutic landscape. As a humanized monoclonal antibody, it is designed to selectively bind to soluble amyloid-beta protofibrils, which are believed to be particularly neurotoxic, and facilitate their removal. Following rigorous clinical trials, the therapy received accelerated approval from the U.S. Food and Drug Administration (FDA), offering a glimmer of hope to patients and their families. Despite its approval and demonstrated efficacy in slowing disease progression, a complete understanding of its exact mode of action had eluded scientists. Furthermore, anti-amyloid antibody therapies, including lecanemab, have been associated with side effects such as Amyloid-Related Imaging Abnormalities (ARIA), which manifest as transient edema or microhemorrhages in the brain, underscoring the need for more precise and safer treatment modalities.
Antibodies, fundamental components of the adaptive immune system, are Y-shaped proteins composed of two main functional regions. The ‘Fragment antigen-binding’ (Fab) region is highly variable and responsible for recognizing and binding specifically to a target antigen – in lecanemab’s case, amyloid-beta protofibrils. The ‘Fragment crystallizable’ (Fc) region, on the other hand, is conserved and interacts with various immune cells and molecules, thereby orchestrating downstream immune responses. While earlier investigations had implicated microglia in the process of amyloid plaque clearance, direct experimental proof linking their activation specifically to lecanemab’s effectiveness, particularly through its Fc fragment, remained elusive. Some scientific hypotheses even posited that plaque removal might occur independently of the Fc fragment’s involvement, through mechanisms like direct amyloid dissolution or peripheral sink effects. The recent study decisively disproved these alternative theories, establishing the Fc fragment as an indispensable component for the therapeutic action.
To unravel this complex interplay, the research team at VIB-KU Leuven employed an innovative experimental strategy. They utilized a unique Alzheimer’s mouse model engineered to harbor human microglial cells. This "humanized" model provided an unprecedented platform to meticulously observe how lecanemab interacts with human immune cells in a living system and to precisely quantify its impact on plaque removal. The distinct advantage of this model lies in its ability to circumvent species-specific differences that often limit the translatability of findings from standard murine models to human patients. Magdalena Zielonka, a co-first author of the study, emphasized the critical nature of using human microglia in a controlled experimental setting, noting that it allowed for the testing of the very antibodies administered to patients and enabled the observation of human-specific cellular responses with unparalleled resolution. Crucially, when the Fc fragment of lecanemab was surgically removed or rendered non-functional in their experiments, the antibody completely lost its therapeutic effect on plaque clearance, providing irrefutable evidence of its necessity.
Further delving into the cellular mechanics, the scientists meticulously examined how activated microglia physically remove amyloid plaques within this sophisticated hybrid model. Their investigations identified key intracellular processes that were specifically triggered in the presence of an intact Fc fragment. These included robust phagocytosis – the cellular process where microglia engulf and internalize the amyloid plaques – followed by enhanced lysosomal activity, which is essential for the breakdown and degradation of the internalized material. Without the functional Fc fragment, these vital cleanup pathways remained dormant, confirming that the Fc-mediated interaction was the critical switch for initiating the microglial plaque-clearing program.
The research team employed cutting-edge molecular techniques, including single-cell and spatial transcriptomics, to gain a deeper understanding of the genetic changes accompanying microglial activation. Single-cell transcriptomics allows scientists to analyze gene expression profiles of individual cells, revealing cellular heterogeneity and specific states. Spatial transcriptomics, an even newer technique, maps gene expression patterns while preserving the spatial context within tissue, providing insights into cellular interactions and tissue organization. Using these powerful methods, including NOVA-ST – a novel spatial transcriptomics analysis method developed by the Stein Aerts lab at VIB-KU Leuven – the researchers identified a distinct gene activity pattern within microglia that correlated directly with effective plaque removal. This pattern included the strong expression of the gene SPP1, which encodes osteopontin, a protein known to play roles in inflammation, tissue remodeling, and macrophage activation. This molecular signature provided a definitive fingerprint of the "reprogrammed" microglia engaged in therapeutic amyloid clearance. Dr. Giulia Albertini, another co-first author, articulated that their study clearly demonstrated how this anti-amyloid antibody therapy works, highlighting that its efficacy hinges on the antibody’s Fc fragment activating microglia to efficiently clear amyloid plaques. She further elaborated that the Fc fragment essentially functions as an anchor, allowing microglia to attach to plaques and subsequently undergo a reprogramming process that enhances their clearance capabilities.
The profound insights gleaned from this research extend far beyond merely understanding lecanemab. By precisely defining the microglial program responsible for amyloid plaque clearance, these findings illuminate new avenues for developing next-generation Alzheimer’s therapies. The knowledge that the Fc fragment initiates this specific immune response opens the door to innovative strategies that might directly activate microglia, circumventing the need for antibodies altogether. Such approaches could involve small molecules designed to mimic the Fc fragment’s signaling, or gene therapies engineered to upregulate the beneficial microglial activation pathways identified in the study. Professor Bart De Strooper, who led the research team, concluded that this fundamental understanding not only clarifies the importance of the Fc fragment but also provides crucial guidance for the rational design of future Alzheimer’s drugs, potentially leading to therapies that are more targeted, effective, and perhaps, with a reduced side effect profile.
This comprehensive investigation, conducted at the VIB-KU Leuven Center for Brain & Disease Research, represents a monumental stride in Alzheimer’s research. Its success was underpinned by the generous support of numerous international funding bodies, including the European Research Council (ERC), the Alzheimer’s Association USA, the Research Foundation Flanders (FWO), the Queen Elisabeth Medical Foundation for Neurosciences, Stichting Alzheimer Onderzoek – Fondation Recherche Alzheimer (STOPALZHEIMER.BE), KU Leuven, VIB, and the UK Dementia Research Institute at University College London. The collaborative spirit and diverse funding mechanisms underscore the global commitment required to confront the complexities of neurodegenerative diseases and translate groundbreaking discoveries into tangible hope for patients worldwide.
About the Author
